Weight Loss Drugs Exam 1

obesity

• medical condition in which excess body fat adversely affects health

anorexiant

• a category of drugs that reduce appetite

anorexia

• clinical term for reduced apetite

diet and exercise

primary therapy for patients with obesity

anorexiant adjunctive therapy

• additional treatment used alongside primary therapies (diet and exercise) to enhance weight loss outcomes.

BMI

• measurement that evaluates body weight in relation to height, used to categorize underweight, normal weight, overweight, and obesity.

• not an accurate measure to obesity as it does not account for muscle mass or fat distribution.

waist circumference/ abdominal fat

• best predictor of obesity related disease

phentermine

• Adipex P

phentermine (Adipex P)

• CIV

• sympathomimetic (satiety center)

• short term weight management- best 3 weeks on then off for a month

• 1 x daily

• called speckled bird egg

1 x daily

phentermine dosing interval

phentermine MOA

• stimulates CNS → increases Norepi

• stimulate satiety center (feel full)

bupropion, naltexone

Contrave

bupropion, naltrexone (Contrave)

• antidepressant + naltrexone

• when combined are anorexiant

• mesolimbic dopamine circuit→ brain’s reward system

• chronic weight management

• 2 x daily

• decreases craving for food, especially sweets

2 x daily

bupropion/naltrexone (Contrave) dosing interval

phentermine/topiramate

Qsymia

phentermine/topiramate (Qsymia)

• CIV

• sympathomimetic, anticonvulsant

• REMS program- risk evaluation and mitigation strategies→ risk of birth defects

• chronic weight management

• 1 x daily

• stimulates satiety center

1 x daily

phentermine/topiramate (Qsymia) dosing interval

GLP-1 Receptor Agonist

• A class of medication that mimics the effects of the glucagon-like peptide-1 hormone, promoting insulin secretion, reducing appetite, and improving glycemic control in patients with type 2 diabetes. Commonly used for weight management.

• some indicated for weight loss- delay gatric emptying, also stimulate satiety center

• some for diabetes - stimulate insulin secretion

Victoza, Ozempic, Rybelsus

GLP-1 Receptor Agonists for diabetes

Saxenda, Wegovy

GLP-1 Receptor Agonist for chromic weight managment

liraglutide

Saxenda

liraglutide (Saxenda)

• parenteral (SQ injection in multiuse pen)

• chronic weight management

• GLP-1 Receptor Agonist

• 1 x daily

1 x daily

liraglutide (Saxenda) dosing interval

semaglutide

Wegovy

semaglutide (Wegovy)

• parenteral (SQ injection with a single use pen)

• chronic weight management

• 1 x weekly

• GLP-1 Receptor Agonsit

1 x weekly

semaglutide (Wegovy) dosing interval

GIP Receptor Agonists

• a class of medications that stimulate insulin secretion in response to glucose, primarily used for managing type 2 diabetes. They also have potential effects on weight loss.

• delay gastric emptying and stimulate satiety center

• tirzepatide (Zepbound, Mounjaro)

tirzepatide

Zepbound

tirzepatide (Zepbound)

• parenteral (SQ injection with a single use pen)

• chronic weight managment

• GIP Receptor agonists

• 1 x weekly

• Mounjaro (antidiabetic)

1 x weekly

tirzepatide (Zepbound) dosing interval

Alli

60mg capsule orlistat OTC

Xenical

120 mg capsule orlistat RX

orlistat

• not an anorexiant

• 60 mg capsule (Alli- OTC)

• 120 mg capsule (Xenical-Rx)

• 3 x daily with food

• category (lipase inhibitor)- inhibits gastrointestinal lipase enzymes→ dietary fat not metabolized or absorbed

• causes diarrhea- very abrupt

• chronic weight management

3 x daily with food

orlistat dosing interval

psyllium

• reduces the side effects of orlistat by the seeds absorbing water and making stool bulkier